Dova Pharmaceuticals (Dova Pharmaceuticals) Total Inventories : $4.68 Mil (As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Total Inventories?

Dova Pharmaceuticals's total inventories for the quarter that ended in Sep. 2019 was $4.68 Mil. Dova Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2019 to the quarter that ended in Sep. 2019 was $4.43 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Dova Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2019 was $0.90.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Dova Pharmaceuticals's Days Inventory for the three months ended in Sep. 2019 was 618.35.

Inventory Turnover measures how fast the company turns over its inventory within a year. Dova Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2019 was 0.15.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Dova Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2019 was 1.31.

Dova Pharmaceuticals Total Inventories Historical Data

The historical data trend for Dova Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Total Inventories Chart

Dova Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Total Inventories

4.39

Dova Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Inventories	Get a 7-Day Free Trial									1.78	4.39	4.31	4.17	4.68

Dova Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Dova Pharmaceuticals (NAS:DOVA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Dova Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2019 is

	Net-Net Working Capital Per Share (Q: Sep. 2019 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(68.448	+	0.75 * 1.244	+	0.5 * 4.683	-	45.712
-	0	-	0)	/	28.8214
=	0.90

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Dova Pharmaceuticals's Days Inventory for the three months ended in Sep. 2019 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2019 )	/	Cost of Goods Sold (Q: Sep. 2019 )	*	Days in Period
	=	4.425	/	0.653	*	365 / 4
	=	618.35

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Dova Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2019 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2019 )	/	Average Total Inventories (Q: Sep. 2019 )
	=	0.653	/	4.425
	=	0.15

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Dova Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2019 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2019 )	/	Revenue (Q: Sep. 2019 )
	=	4.425	/	3.373
	=	1.31

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Dova Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707

Website

http://www.dova.com

Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.

Executives

Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd	officer: Chief Medical Officer	C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs	director
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli	director, officer: President & CEO	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt	officer: Chief Commercial Officer	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir	director, officer: President & CEO	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707